Adenovirus vector pseudotyping in fiber-expressing cell lines: Improved transduction of Epstein-Barr virus-transformed B cells

Journal of Virology

Volumn 74, Issue 1, 2000, Pages 354-362

  Von Seggern, Dan J ^a   Huang, Shuang ^a   Fleck, Shonna Kaye ^a   Stevenson, Susan C ^b   Nemerow, Glen R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; B LYMPHOCYTE; CELL LINE; CELL TRANSFORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EXPRESSION VECTOR; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; VIRUS TYPING;

EID: 0033989720     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.1.354-362.2000     Document Type: Article

References (60)

1. Bashir, R., J, Luka, K. Cheloha, M. Chamberlain, and F. Hoehberg. 1993. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology 43:2358-2361.
2. Bergelson, J. M. 1999. Receptors mediating adenovirus attachment and internalization. Biochem. Pharmacol. 57:975-979.
3. Bergelson, J. M., J. A. Cunningham, G. Droguett, E. A. Kurt-Jones, A. Krithivas, J. S. Hong, M. S. Horwitz, R. L. Crowell, and R. W. Finberg. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
4. Chee-Sheung, C. C., and H. S. Ginsberg. 1982. Characterization of a temperature-sensitive fiber mutant of type 5 adenovirus and effect of the mutation on virion assembly. J. Virol. 42:932-950.
5. Curiel, T. J., D. R. Cook, C. Bogedain, W. Jilg, G. S. Harrison, M. Cotten, D. T. Curiel, and E. Wagner. 1999. Efficient foreign gene expression in Epstein-Barr virus-transformed human B-cells. Virology 198:577-585.
6. Defer, C., M.-T. Belin, M.-L. Caillet-Boudin, and P. Boulanger. 1990. Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J. Virol. 64:3661-3673.
7. D'Halluin, J.-C., M. Milleville, G. R. Martin, and P. Boulanger. 1980. Morphogenesis of human adenovirus type 2 studied with fiber- and fiber and penton base-defective temperature-sensitive mutants. J. Virol. 33:88-99.
8. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:9706-9713.
9. Ernberg, I., and E. Altiok. 1989. The role of Epstein-Barr virus in lymphomas of HIV carriers. APMIS 97:58-61.
10. Falgout, B., and G. Ketner. 1988. Characterization of adenovirus particles made by deletion mutants lacking the fiber gene. J. Virol. 62:622-625.
11. Franken, M., A. Estabrooks, L. Cavacini, B. Sherburne, F. Wang, and D. T. Scadden. 1996. Epstein-Barr virus-driven gene therapy for EBV-relaled lymphomas. Nat. Med. 2:1379-1382.
12. Gall, J., A. Kass-Eisler, L. Leinwand, and E. Falck-Pedersen. 1996 Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70:2116-2123.
13. Goldman, C. K., B. E. Rogers, J. T. Douglas, B. A. Sosnowski, W. Ying, G. P. Siegal, A. Baird, J. A. Campain, and D. T. Curiel. 1997. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57:1447-1451.
14. Gorziglia, M. I., M. J. Kadan, S. Vei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
15. Haddada, H., L. Cordier, and M. Perricaudet. 1995. Gene therapy using adenovirus vectors. Curr. Top. Microbiol. Immunol. 199:297-306.
16. Hamilton-Dutoit, S. J., M. Raphael, J. Audouin, J. Diebold, I. Lisse, C. Pedersen, E. Oksenhendler, L. Marelle, and G. Pallesen. 1993. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 82:619-625.
17. Huang, S., D. G. Stupack, P. Mathias, Y. Wang, and G. Nemerow. 1997. Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc. Natl. Acad. Sci. USA 94:8156-8161.
18. Huard, J., H. Lochmüller, G. Acsadi, A. Jani, B. Massie. and G. Karpati. 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2:107-115.
19. Jansen-Durr, P., H. Boeuf, and C. Kédinger. 1988 Replication-induced stimulation of the major late promoter of adenovirus is correlated to the binding of a factor to sequences in the first intron. Nucleic Acids Res. 16:3771-3786.
20. Jooss, K., Y. Yang, K. J. Fisher, and J. M. Wilson. 1998. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72:4212-4223.
21. Judde, J.-G., G. Spangler, I. Magrath, and K. Bhatia. 1996. Use ot Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum. Gene Ther. 7:647-653.
22. Kenney, S., J.-Q. Ge, E. M. Westphal, and J. Olsen. 1998. Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Hum. Gene Ther. 9:1131-1141.
23. Kovesdi, I., D. E. Brough. J. T. Bruder, and T. J. Wickham. 1997. Adenoviral vectors for gene transfer. Curr. Opin. Biotechnol. 8:583-589.
24. Kozarsky, K. F., and J. M. Wilson. 1993. Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev. 3:499-503.
25. Krasnykh, V., I. Dmitriev, G. Mikheeva, C. R. Miller, N. Belousova, and D. T. Curiel. 1998. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72:1844-1852.
26. Krasnykh, V. N., G. V. Mikheeva, J. T. Douglas, and D. T. Curiel. 1996. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70:6839-6846.
27. Legrand, V., D. Spehner, Y. Schlesinger, N. Settelen, A. Pavirani, and M. Mehtali. 1999. Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber. J. Virol. 73:907-919.
28. Leon, R. P., T. Hedlund, S. J. Meech, S. Li, J. Schaack, S. P. Hunger, R. C. Duke, and J. DeGregori. 1998. Adenoviral-mediated gene transfer in lymphocytes. Proc. Natl. Acad. Sci. USA 95:13159-13164.
29. Leong, K., W. Lee, and A. J. Berk. 1990. High-level transcription from the adenovirus major late promoter requires downstream binding sites for late-phase-specific factors. J. Virol. 64:51-60.
30. Lucas, K. G., K. E. Pollok, and D. J. Emanuel. 1997. Post-transplant EBV induced lymphoproliferative disorders. Leuk. Lymphoma 25:1-8.
31. Lukashok, S. A., and M. S. Horwitz. 1998. New perspectives in adenovirus. Curr. Clin. Top. Infect. Dis. 18:286-304.
32. MacMahon, E. M. E., J. D. Glass, S. D. Hayward, R. B. Mann, P. S. Becker, P. Charache, J. C. McArthur, and R. F. Ambinder. 1991. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969-973.
33. Mansour, S. L., T. Grodzicker, and R. Tjian. 1986. Downstream sequences affect transcription initiation from the adenovirus major late promoter. Mol. Cell. Biol. 6:2684-2694.
34. Mason, B. B., A. R. Davis, B. M. Bhat, M. Chengalvala, M. D. Lubeck, G. Zandle, B. Kostek, S. Cholodofsky, S. Dheer, K. Molnar-Kimber, S. Mizutani, and P. P. Hung, 1990. Adenovirus vaccine vectors expressing hepatitis B surface antigen: importance of regulatory elements in the adenovirus major late intron. Virology 177:452-461.
35. Mathias, P., T. J. Wickham, M. Moore, and G. Nemerow. 1994. Multiple adenovirus serotypes use αν integrins for infection. J. Virol. 68:6811-6814.
36. Michael, S. I., J. S. Hong, D. T. Curiel, and J. A. Engler. 1995. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 2:660-668.
37. Mittereder, N., K. L. March, and B. C. Trapnell. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:7498-7509.
38. Nalbantoglu, J., G. Pari, G. Karpati, and P. C. Holland. 1999. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther. 10:1009-1019.
39. Philipson, L., K. Lonberg-Holm, and U. Pettersson. 1968. Virus-receptor interaction in an adenovirus system. J. Virol. 2:1064-1075.
40. Rancourt, C., B. E. Rogers, B. A. Sosnowski, M. Wang, A. Piché, G. F. Pierce, R. D. Alvarez, G. P. Siegal, J. T. Douglas, and D. T. Curiel. 1998. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4:2455-2461.
41. Roelvink, P. W., A. Lizonova, J. G. M. Lee, Y. Li, J. M. Bergelson, R. W. Finberg, D. E. Brough, I. Kovesdi, and T. J. Wickham. 1998. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72:7909-7915.
42. Rogers, R. P., J.-Q. Ge, E. Holley-Guthrie, D. K. Hoganson, K. E. Comstock, J. C. Olsen, and S. Kenney. 1996. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum. Gene Ther. 7:2235-2245.
43. Sheay, W., S. Nelson, I. Martinez, T.-H. T. Chu, S. Bhatia, and R. Dornburg. 1993. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. Bio Techniques 15:856-862.
44. Smith, T. A. G., M. G. Mehaffey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:397-402.
45. Stevenson, S. C., M. Rollence, J. Marshall-Neff, and A. McClelland. 1197. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J. Virol. 71:4782-4790.
46. Stevenson, S. C., M. Rollence, B. White, L. Weaver, and A. McClelland. 1995. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J. Virol. 69:2850-2857.
47. Teoh, G., L. Chen, M. Urashima, Y.-T. Tai, L. A. Celi, D. Chen, D. Chauhan, A. Ogata, R. W. Finberg, I. J. Webb, D. W. Kufe, and K. C. Anderson. 1998. Adenovirus vector-based purging of multiple myeloma cells. Blood 92:4591-4601.
48. Thomas, J. A., M. J. Allday, and D. H. Crawford. 1991. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res. 57:329-380.
49. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94:3352-3356.
50. Von Seggern, D. J., C. Y. Chiu, S. K. Fleck, P. L. Stewart, and G. R. Nemerow. 1999. A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. J. Virol. 73:1601-1608.
51. Von Seggern, D. J., J. Kehler, R. Endo, and G. R. Nemerow. 1998. Complementation of a fiber mutant adenovirus by packaging cell lines stably expressing the Ad5 fiber protein. J. Gen. Virol. 79:1461-1468.
52. Von Seggern, D. J., and G. R. Nemerow. 1999. Adenoviral vectors for protein expression, p. 111-156. In J. Fernandez and J. Hoeffler (ed.), Gene expression systems: using nature for the art of expression. Academic Press, San Diego, Calif.
53. Walters, R. W., T. Grunst, J. M. Bergelson, R. W. Finberg, M. J. Welsh, and J. Zabner. 1999. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J. Biol. Chem. 274: 10219-10226.
54. Watkins, S. J., V. V. Mesyanzhinov, L. P. Kurochkina, and R. E. Hawkins. 1997. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4:1004-1012.
55. Weiss, L. M., L. A. Movahed, R. A. Warnke, and J. Sklar. 1989. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 320:502-506.
56. Westphal, E.-M., A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and S. C. Kenney. 1999. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res. 59:1485-1491.
57. 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.
58. Wickham, T. J., E. Tzeng, L. L. Shears II, P. W. Roelvink, Y. Li, G. M. Lee, D. E. Brough, A. Lizonova, and I. Kovesdi. 1997. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71:8221-8229.
59. Yeh, P., J.-F. Dedieu, C. Orsini, E. Vigne, P. Denefle, and M. Perricaudet. 1996. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70:559-565.
60. Zhong, L., A. Granelli-Piperno, Y. Choi, and R. M. Steinman. 1999. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29:964-972.